Profiling microbiome and metabolites in children with obstructive sleep apnea
Microbiome and Metabolomics Profiling in Children With Obstructive Sleep Apnoea
This study looks at the differences in gut bacteria and urine chemicals between children with obstructive sleep apnea and those without to see how these might be related to the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 130 (estimated) |
| Ages | 6 Years to 11 Years |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06452992 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the differences in microbiome composition and urine metabolomic profiles between children aged 6-11 with obstructive sleep apnea (OSA) and those without. By comparing nasal and stool samples, as well as urine metabolites, the study seeks to uncover potential pathological processes associated with OSA. The hypothesis is that children with OSA will exhibit distinct microbiome and metabolomic profiles compared to non-OSA controls, which may be linked to inflammatory responses. This research could provide insights into the underlying mechanisms of OSA and its related health impacts.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 6-11 years diagnosed with obstructive sleep apnea.
Not a fit: Patients with previous upper airway surgery, genetic or syndromal diseases, or other specified conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of the biological factors contributing to obstructive sleep apnea in children, potentially guiding future treatments.
How similar studies have performed: While the specific approach of combining microbiome and metabolomic profiling in OSA is relatively novel, previous studies have indicated potential links between microbiome changes and various health conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children aged 6-11 years old Exclusion Criteria: * Previous upper airway surgery, genetic or syndromal disease, congenital or acquired neuromuscular disease, suspected or confirmed congenital or acquired immunodeficiency, known metabolic syndrome, craniofacial abnormalities, structural or congenital heart disease, use of medications or therapy that could affect immunity such as systemic corticosteroids, chemotherapy, radiation therapy, intravenous immunoglobulins.
Where this trial is running
Hong Kong
- Prince of Wales Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Kate Ching Ching Chan, MD — Chinese University of Hong Kong
- Study coordinator: Kate Ching Ching Chan, MD
- Email: katechan@cuhk.edu.hk
- Phone: 35053515
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.